2009 milestones

2009 milestones

Selected products with Phase III or regulatory milestones expected in 2009. (A) The long-acting release formulation of Byetta exenatide uses Medisorb drug delivery technology from Alkermes (NASDAQ:ALKS); (B) Endo (NASDAQ:ENDP) is acquiring Indevus (NASDAQ:IDEV)

Company Product Indication Event Milestone
Abbott (NYSE:ABT)/AstraZeneca (LSE:AZN; NYSE:AZN) Crestor rosuvastatin and TriLipix (ABT-335) combination Dyslipidemia Submit NDA 2H09
Accentia (Pink:ABPI) Biovaxid Indolent follicular B cell non- Hodgkin's lymphoma (NHL) Submit BLA and MAA 1H09
Acorda (NASDAQ:ACOR) Fampridine-SR Multiple sclerosis (MS) Submit NDA; submit MAA 1Q09; 2009
Actelion (SWX:ATLN) Pivlaz clazosentan Prevent the occurrence of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH) Ph III data 2H09
Actelion (SWX:ATLN)/ GlaxoSmithKline (LSE:GSK; NYSE:GSK) Almorexant Insomnia Ph III data 2H09
Acusphere (NASDAQ:ACUS)/ Nycomed Imagify perflubutane Coronary heart disease (CAD) Submit MAA 2009
Aeterna Zentaris (TSX:AEZ; NASDAQ:AEZS)/Merck KGaA(Xetra:MRK)/Shionogi/Nippon Kayaku (Tokyo:4272) Cetrotide cetrorelix Benign prostatic hyperplasia (BPH) Ph III data 3Q09
AGI (ISE:A9I; LSE:AGI) Rezular averapamil (AGI-003) Diarrhea-predominant irritable bowel syndrome (IBS-D) Prelim Ph III data 1H09

Read the full 2027 word article

How to gain access

Continue reading with a
two-week free trial.